CARDIOGENESIS REPORTS THIRD QUARTER, NINE-MONTH RESULTS
Page 3-3-3
prior year's third quarter. The Company's dominant share of the laser-based cardiac
revascularization market includes substantial penetration in the top cardiovascular institutions in the
U.S.
Conference Call
CardioGenesis will host a conference call today at 11:30 a.m. EDT (Eastern), which will be
broadcast live over the Internet, to discuss the Company's results for the third quarter ended
September 30, 2002. Those interested in listening to the live webcast of the conference call may do
so by going to the Company's website at
www.cardiogenesis.com
.
Web participants are encouraged to go to the Company's website at least 15 minutes prior to
the start of the call to register and, if necessary, download and install any needed audio software. An
online webcast replay of the call will be accessible at
www.cardiogenesis.com
for seven days
starting shortly after the live webcast.
About CardioGenesis Corporation
CardioGenesis is a medical device company specializing in the treatment of cardiovascular
disease and is the leader in products that stimulate cardiac angiogenesis. The Company's market
leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a
FDA-cleared surgical procedure known as transmyocardial revascularization (TMR) to treat
patients suffering from angina. The CardioGenesis TMR procedure, which is marketed in the U.S.
and around the world, has been shown to reduce angina and improve the quality of life in patients
with coronary artery disease. The Company's minimally invasive PMR procedure is currently being
marketed in Europe and other international markets.
For more information on the Company and its products, please visit the CardioGenesis web
site at
http://www.cardiogenesis.com
. For investor relations information, visit the CardioGenesis
pages in the "Client" section of the Allen & Caron Inc web site at
www.allencaron.com
.
Any forward-looking statements in this news release related to the Company's sales, profitability, the adoption of its
technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous
risks and uncertainties that could cause actual results to differ materially. Other factors that could cause CardioGenesis'
actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2001, its Quarterly Report on Form 10-Q for the second quarter ended June 30,
2002, and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-
looking statements as a result of developments occurring after the date of this press release.
TABLES FOLLOW
